Motivated Behavior in Adults With and Without ADHD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-07

Study Completion Date

2018-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the effects of methylphenidate on motivated behavior in adults with and without ADHD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Motivation and Methylphenidate

NCT03190681

Motivation Apathy Impulsive Behavior

COMPLETED EARLY_PHASE1

Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder

NCT00223561

ADHD

COMPLETED PHASE4

Treatment of Patients With Alcoholism and Attention Deficit Disorder

NCT00261872

Alcoholism Attention Deficit Disorder

COMPLETED PHASE4

The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment

NCT02180529

Mild Cognitive Impairment (MCI)

TERMINATED NA

Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00050622

Attention Deficit Disorder With Hyperactivity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study has a mixed between- and within-subject design. Participants are young adults (aged 18-45) with ADHD and non-ADHD matched controls. They will be recruited from locations around the community, consented, screened for eligibility, then scheduled for 2 study days. Study days will be at least 48 hours apart. Thus, there will be a total of 3 lab visits across a 3 week period. Participants will be administered study drug on one study day and placebo on the other study day. They will complete a battery of cognitive/behavioral tasks and answer questionnaires on both study days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

There are two parallel arms of this study (ADHD or non-ADHD subjects).

Within each arm, each subject will be exposed to placebo and a drug (each at a different timepoint in the study). Although all subjects will receive both placebo and the drug, the order of presentation of the placebo and drug is counterbalanced across subjects (i.e., approximately half will receive the drug first and approximately half will receive the placebo first).

For both study arms, regardless of whether the placebo is received first or second, the outcome measure will be calculated as the number of high effort selections.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADHD group

Adults with ADHD

Group Type EXPERIMENTAL